1 1866 143 RANDOMIZED TRIAL OF TIBETAN YOGA IN PATIENTS WITH BREAST CANCER UNDERGOING CHEMOTHERAPY. BACKGROUND: THE CURRENT RANDOMIZED TRIAL EXAMINED THE EFFECTS OF A TIBETAN YOGA PROGRAM (TYP) VERSUS A STRETCHING PROGRAM (STP) AND USUAL CARE (UC) ON SLEEP AND FATIGUE IN WOMEN WITH BREAST CANCER WHO WERE UNDERGOING CHEMOTHERAPY. METHODS: WOMEN WITH STAGE (AMERICAN JOINT COMMITTEE ON CANCER (AJCC) TNM) I TO III BREAST CANCER WHO WERE UNDERGOING CHEMOTHERAPY WERE RANDOMIZED TO TYP (74 WOMEN), STP (68 WOMEN), OR UC (85 WOMEN). PARTICIPANTS IN THE TYP AND STP GROUPS PARTICIPATED IN 4 SESSIONS DURING CHEMOTHERAPY, FOLLOWED BY 3 BOOSTER SESSIONS OVER THE SUBSEQUENT 6 MONTHS, AND WERE ENCOURAGED TO PRACTICE AT HOME. SELF-REPORT MEASURES OF SLEEP DISTURBANCES (PITTSBURGH SLEEP QUALITY INDEX), FATIGUE (BRIEF FATIGUE INVENTORY), AND ACTIGRAPHY WERE COLLECTED AT BASELINE; 1 WEEK AFTER TREATMENT; AND AT 3, 6, AND 12 MONTHS. RESULTS: THERE WERE NO GROUP DIFFERENCES NOTED IN TOTAL SLEEP DISTURBANCES OR FATIGUE LEVELS OVER TIME. HOWEVER, PATIENTS IN THE TYP GROUP REPORTED FEWER DAILY DISTURBANCES 1 WEEK AFTER TREATMENT COMPARED WITH THOSE IN THE STP (DIFFERENCE, -0.43; 95% CONFIDENCE INTERVAL [95% CI], -0.82 TO -0.04 [P = .03]) AND UC (DIFFERENCE, -0.41; 95% CI, -0.77 TO -0.05 [P = .02]) GROUPS. GROUP DIFFERENCES AT THE OTHER TIME POINTS WERE MAINTAINED FOR TYP VERSUS STP. ACTIGRAPHY DATA REVEALED GREATER MINUTES AWAKE AFTER SLEEP ONSET FOR PATIENTS IN THE STP GROUP 1 WEEK AFTER TREATMENT VERSUS THOSE IN THE TYP (DIFFERENCE, 15.36; 95% CI, 7.25-23.48 [P = .0003]) AND UC (DIFFERENCE, 14.48; 95% CI, 7.09-21.87 [P = .0002]) GROUPS. PATIENTS IN THE TYP GROUP WHO PRACTICED AT LEAST 2 TIMES A WEEK DURING FOLLOW-UP REPORTED BETTER PITTSBURGH SLEEP QUALITY INDEX AND ACTIGRAPHY OUTCOMES AT 3 MONTHS AND 6 MONTHS AFTER TREATMENT COMPARED WITH THOSE WHO DID NOT AND BETTER OUTCOMES COMPARED WITH THOSE IN THE UC GROUP. CONCLUSIONS: PARTICIPATING IN TYP DURING CHEMOTHERAPY RESULTED IN MODEST SHORT-TERM BENEFITS IN SLEEP QUALITY, WITH LONG-TERM BENEFITS EMERGING OVER TIME FOR THOSE WHO PRACTICED TYP AT LEAST 2 TIMES A WEEK. CANCER 2018;124:36-45. (C) 2017 AMERICAN CANCER SOCIETY. 2018 2 1980 55 SLEEP MODERATES THE EFFECTS OF TIBETAN YOGA FOR WOMEN WITH BREAST CANCER UNDERGOING CHEMOTHERAPY. THIS STUDY EXAMINED SELF-REPORTED AND ACTIGRAPHY-ASSESSED SLEEP AND DEPRESSION AS MODERATORS OF THE EFFECT OF A TIBETAN YOGA INTERVENTION ON SLEEP AND DEPRESSION AMONG WOMEN UNDERGOING CHEMOTHERAPY FOR BREAST CANCER. THIS IS A SECONDARY ANALYSIS OF AN RCT EXAMINING A 4-SESSION TIBETAN YOGA PROGRAM (TYP; N = 74) VERSUS STRETCHING PROGRAM (STP; N = 68) OR USUAL CARE (UC; N = 85) ON SELF-REPORTED SLEEP (PITTSBURGH SLEEP QUALITY INDEX (PSQI), ACTIGRAPHY-ASSESSED SLEEP EFFICIENCY (SE)) AND DEPRESSION (CENTERS FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CES-D) FOR WOMEN UNDERGOING CHEMOTHERAPY FOR BREAST CANCER. DATA WERE COLLECTED AT BASELINE AND 1-WEEK AND 3-MONTH POST-INTERVENTION. BASELINE PSQI, ACTIGRAPHY-SE, AND CES-D WERE EXAMINED AS MODERATORS OF THE EFFECT OF GROUP ON PSQI, ACTIGRAPHY-SE, AND CES-D 1 WEEK AND 3 MONTHS AFTER TREATMENT. THERE WAS A SIGNIFICANT BASELINE ACTIGRAPHY-SE X GROUP EFFECT ON PSQI AT 1 WEEK (P < .001) AND 3 MONTHS (P = .002) AND ON CES-D AT 3 MONTHS (P = .049). SPECIFICALLY, THE NEGATIVE ASSOCIATION OF BASELINE ACTIGRAPHY-SE WITH SUBSEQUENT PSQI AND CES-D WAS BUFFERED FOR WOMEN IN THE TYP AND, TO A LESSER EXTENT IN STP, COMPARED TO THOSE IN THE UC. BASELINE PSQI AND CES-D WERE NOT SIGNIFICANT MODERATORS OF THE EFFECT OF GROUP ON ANY OUTCOME. BEHAVIORALLY ASSESSED SLEEP MAY BE A MORE ROBUST INDICATOR OF WHICH PATIENTS ARE MOST APPROPRIATE FOR A YOGA INTERVENTION THAN SELF-REPORTED SLEEP QUALITY. WOMEN WITH POOR SLEEP EFFICIENCY MAY DERIVE THE GREATEST BENEFIT IN TERMS OF SLEEP QUALITY AND MOOD FROM A YOGA INTERVENTION. 2022 3 891 34 EFFECT OF YOGA-BASED INTERVENTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. BACKGROUND: INFLAMMATORY BOWEL DISEASE (IBD) IS A CHRONIC ILLNESS CHARACTERIZED BY GROSS INFLAMMATION IN THE GASTROINTESTINAL TRACT THAT CAN RESULT IN SYMPTOMS SUCH AS ABDOMINAL PAIN, CRAMPING, DIARRHEA, AND BLOODY STOOLS. IBD IS BELIEVED TO BE INFLUENCED BY PSYCHOLOGICAL FACTORS SUCH AS STRESS AND ANXIETY. THEREFORE, A YOGA INTERVENTION THAT REDUCES STRESS AND ANXIETY MAY BE AN EFFECTIVE COMPLEMENTARY TREATMENT FOR THESE DISORDERS. MATERIAL AND METHODS: A TOTAL OF 100 IBD PATIENTS [ULCERATIVE COLITIS (UC) N = 60 AND CROHN'S DISEASE (CD) N = 40] DURING THE CLINICAL REMISSION PHASE OF DISEASE WERE INCLUDED IN THE STUDY. THESE PATIENTS WERE ALLOCATED RANDOMLY TO EITHER THE YOGA GROUP THAT UNDERWENT AN 8-WEEK YOGA INTERVENTION (PHYSICAL POSTURES, PRANAYAMA, AND MEDITATION) 1- HOUR/DAY IN ADDITION TO STANDARD MEDICAL THERAPY (UC, N = 30; CD, N = 20) OR THE CONTROL GROUP (UC, N = 30; CD N = 20), WHICH CONTINUED WITH STANDARD MEDICAL THERAPY ALONE. THE MAIN OUTCOME MEASURES WERE CARDIOVASCULAR AUTONOMIC FUNCTIONS, SERUM EOSINOPHILIC CATIONIC PROTEIN, INTERLEUKIN- 2 SOLUBLE RECEPTORS, SPEILBERGER'S STATE TRAIT ANXIETY INVENTORY (STAI) SCORES, AND CLINICAL SYMPTOMS. RESULTS: BEFORE THE INTERVENTION, ALL THE OUTCOME MEASURES WERE COMPARABLE IN THE TWO GROUPS. AFTER THE 8-WEEK YOGA INTERVENTION, FEWER UC PATIENTS REPORTED ARTHRALGIA. THE NUMBER OF PATIENTS REPORTING INTESTINAL COLIC PAIN IN THE CONTROL GROUP WAS HIGHER. STATE AND TRAIT ANXIETY LEVELS WERE SIGNIFICANTLY REDUCED IN PATIENTS WITH UC. HOWEVER, NO SIGNIFICANT CHANGES WERE OBSERVED IN CARDIOVASCULAR AUTONOMIC FUNCTIONS, EOSINOPHILIC CATIONIC PROTEINS, OR INTERLEUKIN-2 SOLUBLE RECEPTORS. CONCLUSIONS: A SIMPLIFIED YOGA-BASED REGIMEN IS A SAFE AND EFFECTIVE COMPLEMENTARY CLINICAL TREATMENT MODALITY FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE DURING THE CLINICAL REMISSION PHASE. 2015 4 2787 41 YOGA THERAPY DECREASES DYSPNEA-RELATED DISTRESS AND IMPROVES FUNCTIONAL PERFORMANCE IN PEOPLE WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A PILOT STUDY. BACKGROUND: THERE HAS BEEN LIMITED STUDY OF YOGA TRAINING AS A COMPLEMENTARY EXERCISE STRATEGY TO MANAGE THE SYMPTOM OF DYSPNEA IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). PURPOSE: THE PRIMARY PURPOSE OF THIS PILOT STUDY WAS TO EVALUATE A YOGA PROGRAM FOR ITS SAFETY, FEASIBILITY, AND EFFICACY FOR DECREASING DYSPNEA INTENSITY (DI) AND DYSPNEA-RELATED DISTRESS (DD) IN OLDER ADULTS WITH COPD. METHODS: CLINICALLY STABLE PATIENTS WITH COPD (N = 29; AGE 69.9 +/- 9.5; FORCED EXPIRATORY VOLUME IN 1 SECOND (FEV(1)) 47.7 +/- 15.6% PREDICTED; FEMALE = 21) WERE RANDOMIZED TO A 12-WEEK YOGA PROGRAM SPECIFICALLY DESIGNED FOR PEOPLE WITH COPD OR USUAL-CARE CONTROL (UC). THE TWICE-WEEKLY YOGA PROGRAM INCLUDED ASANAS (YOGA POSTURES) AND VISAMA VRITTI PRANAYAMA (TIMED BREATHING). SAFETY MEASURE OUTCOMES INCLUDED HEART RATE, OXYGEN SATURATION, DYSPNEA, AND PAIN. FEASIBILITY WAS MEASURED BY PATIENT-REPORTED ENJOYMENT, DIFFICULTY, AND ADHERENCE TO YOGA SESSIONS. AT BASELINE AND AT 12 WEEKS, DI AND DD WERE MEASURED DURING INCREMENTAL CYCLE ERGOMETRY AND A 6-MINUTE WALK (6MW) TEST. SECONDARY EFFICACY OUTCOMES INCLUDED PHYSICAL PERFORMANCE, PSYCHOLOGIC WELL-BEING, AND HEALTH-RELATED QUALITY OF LIFE (HRQOL). RESULTS: YOGA TRAINING WAS SAFE AND FEASIBLE FOR PATIENTS WITH COPD. WHILE YOGA TRAINING HAD ONLY SMALL EFFECTS ON DI AFTER THE 6MW TEST (EFFECT SIZE [ES], 0.20; P = 0.60), THERE WERE GREATER REDUCTIONS IN DD IN THE YOGA GROUP COMPARED TO UC (ES, 0.67; P = 0.08). YOGA TRAINING ALSO IMPROVED 6MW DISTANCE (+71.7 +/- 21.8 FEET VERSUS -27.6 +/- 36.2 FEET; ES = 0.78, P = 0.04) AND SELF-REPORTED FUNCTIONAL PERFORMANCE (ES = 0.79, P = 0.04) COMPARED TO UC. THERE WERE SMALL POSITIVE CHANGES IN MUSCLE STRENGTH AND HRQOL. CONCLUSIONS: ELDERLY PATIENTS WITH COPD PARTICIPATED SAFELY IN A 12-WEEK YOGA PROGRAM ESPECIALLY DESIGNED FOR PATIENTS WITH THIS CHRONIC ILLNESS. AFTER THE PROGRAM, THE SUBJECTS TOLERATED MORE ACTIVITY WITH LESS DD AND IMPROVED THEIR FUNCTIONAL PERFORMANCE. THESE FINDINGS NEED TO BE CONFIRMED IN A LARGER, MORE SUFFICIENTLY POWERED EFFICACY STUDY. 2009 5 774 26 EFFECT OF YOGA AND NATUROPATHY ON DISEASE ACTIVITY AND SYMPTOM BURDENS IN A PATIENT WITH ACTIVE ULCERATIVE COLITIS: A CASE REPORT. OBJECTIVES: ULCERATIVE COLITIS (UC) IS A CHRONIC IDIOPATHIC INFLAMMATORY DISEASE THAT AFFECTS THE LARGE BOWEL. THE OBJECTIVE OF THIS STUDY IS TO FIND THE EFFECT OF YOGA AND NATUROPATHY (YN) IN A PATIENT WITH ACTIVE MODERATE PANCOLITIS. CASE PRESENTATION: AN 18-YEAR OLD UNMARRIED FEMALE DIAGNOSED WITH UC IN 2017. PATIENT'S SYMPTOMS BEGAN WITH ABDOMINAL PAIN, NAUSEA, VOMITING AND DIARRHEA WITH/WITHOUT BLOOD STAINS MORE THAN SEVEN TIMES A DAY, DAILY. THE SYMPTOMS REDUCED AFTER TAKING REGULAR CONVENTIONAL MEDICATION FOR A PERIOD OF ONE-YEAR. HOWEVER, IN FEBRUARY-2019, THE PATIENT VISITED OUR HOSPITAL WITH THE SAME COMPLAINTS AND RECEIVED 21-DAYS OF YN TREATMENTS. RESULTS SHOWED A BETTER REDUCTION IN THE ABDOMINAL PAIN, DISEASE ACTIVITY, STRESS AND DEPRESSION AND A BETTER IMPROVEMENT IN HEMOGLOBIN LEVELS, QUALITY OF SLEEP, AND QUALITY OF LIFE WITH NO ADVERSE EFFECTS. CONCLUSIONS: YN COULD BE CONSIDERED AS AN ALTERNATIVE THERAPY IN THE MANAGEMENT OF UC. HOWEVER, FURTHER STUDIES ARE REQUIRED TO WARRANT THIS EFFECT. 2021 6 2585 29 YOGA FOR HYPERTENSION: A SYSTEMATIC REVIEW OF RANDOMIZED CLINICAL TRIALS. OBJECTIVES: TO CRITICALLY EVALUATE THE EFFECTIVENESS OF YOGA AS A TREATMENT OF HYPERTENSION. METHODS: SEVENTEEN DATABASES WERE SEARCHED FROM THEIR INCEPTIONS TO JANUARY 2014. RANDOMIZED CLINICAL TRIALS (RCTS) WERE INCLUDED, IF THEY EVALUATED YOGA AGAINST ANY TYPE OF CONTROL IN PATIENTS WITH ANY FORM OF ARTERIAL HYPERTENSION. RISK OF BIAS WAS ESTIMATED USING THE COCHRANE CRITERIA. THREE INDEPENDENT REVIEWERS PERFORMED THE SELECTION OF STUDIES, DATA EXTRACTION, AND QUALITY ASSESSMENTS. RESULTS: SEVENTEEN TRIALS MET THE INCLUSION CRITERIA. ONLY TWO RCTS WERE OF ACCEPTABLE METHODOLOGICAL QUALITY. ELEVEN RCTS SUGGESTED THAT YOGA LEADS TO A SIGNIFICANTLY GREATER REDUCTION IN SYSTOLIC BLOOD PRESSURE (SBP) COMPARED TO VARIOUS FORMS OF PHARMACOTHERAPY, BREATH AWARENESS OR READING, HEALTH EDUCATION, NO TREATMENT (NT), OR USUAL CARE (UC). EIGHT RCTS SUGGESTED THAT YOGA LEADS TO A SIGNIFICANTLY GREATER REDUCTION IN DIASTOLIC BLOOD PRESSURE (DBP) OR NIGHT-TIME DBP COMPARED TO PHARMACOTHERAPY, NT, OR UC. FIVE RCTS INDICATED THAT YOGA HAD NO EFFECT ON SBP COMPARED TO DIETARY MODIFICATION (DIM), ENHANCED UC, PASSIVE RELAXATION (PR), OR PHYSICAL EXERCISES (PE). EIGHT RCTS INDICATED THAT YOGA HAD NO EFFECT ON DBP COMPARED TO DIM, ENHANCED UC, PHARMACOTHERAPY, NT, PE, PR, OR BREATH AWARENESS OR READING. ONE RCT DID NOT REPORT BETWEEN-GROUP COMPARISONS. CONCLUSION: THE EVIDENCE FOR THE EFFECTIVENESS OF YOGA AS A TREATMENT OF HYPERTENSION IS ENCOURAGING BUT INCONCLUSIVE. FURTHER, MORE RIGOROUS TRIALS SEEM WARRANTED. 2014 7 1853 35 RANDOMISED CLINICAL TRIAL: YOGA VS WRITTEN SELF-CARE ADVICE FOR ULCERATIVE COLITIS. BACKGROUND: PERCEIVED STRESS SEEMS TO BE A RISK FACTOR FOR EXACERBATION OF ULCERATIVE COLITIS. YOGA HAS BEEN SHOWN TO REDUCE PERCEIVED STRESS. AIMS: TO ASSESS THE EFFICACY AND SAFETY OF YOGA FOR IMPROVING QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS. METHODS: A TOTAL OF 77 PATIENTS (75% WOMEN; 45.5 +/- 11.9 YEARS) WITH ULCERATIVE COLITIS IN CLINICAL REMISSION BUT IMPAIRED QUALITY OF LIFE WERE RANDOMLY ASSIGNED TO YOGA (12 SUPERVISED WEEKLY SESSIONS OF 90 MIN; N = 39) OR WRITTEN SELF-CARE ADVICE (N = 38). PRIMARY OUTCOME WAS DISEASE-SPECIFIC QUALITY OF LIFE (INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE). SECONDARY OUTCOMES INCLUDED DISEASE ACTIVITY (RACHMILEWITZ CLINICAL ACTIVITY INDEX) AND SAFETY. OUTCOMES WERE ASSESSED AT WEEKS 12 AND 24 BY BLINDED OUTCOME ASSESSORS. RESULTS: THE YOGA GROUP HAD SIGNIFICANTLY HIGHER DISEASE-SPECIFIC QUALITY OF LIFE COMPARED TO THE SELF-CARE GROUP AFTER 12 WEEKS (DELTA = 14.6; 95% CONFIDENCE INTERVAL=2.6-26.7; P = 0.018) AND AFTER 24 WEEKS (DELTA = 16.4; 95% CONFIDENCE INTERVAL=2.5-30.3; P = 0.022). TWENTY-ONE AND 12 PATIENTS IN THE YOGA GROUP AND IN THE SELF-CARE GROUP, RESPECTIVELY, REACHED A CLINICAL RELEVANT INCREASE IN QUALITY OF LIFE AT WEEK 12 (P = 0.048); AND 27 AND 17 PATIENTS AT WEEK 24 (P = 0.030). DISEASE ACTIVITY WAS LOWER IN THE YOGA GROUP COMPARED TO THE SELF-CARE GROUP AFTER 24 WEEKS (DELTA = -1.2; 95% CONFIDENCE INTERVAL=-0.1-[-2.3]; P = 0.029). THREE AND ONE PATIENT IN THE YOGA GROUP AND IN THE SELF-CARE GROUP, RESPECTIVELY, EXPERIENCED SERIOUS ADVERSE EVENTS (P = 0.317); AND SEVEN AND EIGHT PATIENTS EXPERIENCED NONSERIOUS ADVERSE EVENTS (P = 0.731). CONCLUSIONS: YOGA CAN BE CONSIDERED AS A SAFE AND EFFECTIVE ANCILLARY INTERVENTION FOR PATIENTS WITH ULCERATIVE COLITIS AND IMPAIRED QUALITY OF LIFE. TRIAL REGISTRATION: CLINICALTRIALS.GOV IDENTIFIER: NCT02043600. 2017 8 2415 48 YOGA AND MEDITATION FOR MENOPAUSAL SYMPTOMS IN BREAST CANCER SURVIVORS-A RANDOMIZED CONTROLLED TRIAL. BACKGROUND: BREAST CANCER SURVIVORS HAVE ONLY VERY LIMITED TREATMENT OPTIONS FOR MENOPAUSAL SYMPTOMS. THE OBJECTIVE OF THIS TRIAL WAS TO EVALUATE THE EFFECTS OF A 12-WEEK TRADITIONAL HATHA YOGA AND MEDITATION INTERVENTION ON MENOPAUSAL SYMPTOMS IN BREAST CANCER SURVIVORS. METHODS: PATIENTS WERE RANDOMLY ASSIGNED EITHER TO A 12-WEEK YOGA AND MEDITATION INTERVENTION OR TO USUAL CARE. THE PRIMARY OUTCOME MEASURE WAS TOTAL MENOPAUSAL SYMPTOMS (MENOPAUSE RATING SCALE [MRS] TOTAL SCORE). SECONDARY OUTCOME MEASURES INCLUDED MRS SUBSCALES, QUALITY OF LIFE (FUNCTIONAL ASSESSMENT OF CANCER THERAPY-BREAST), FATIGUE (FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE), DEPRESSION, AND ANXIETY (HOSPITAL ANXIETY AND DEPRESSION SCALE). OUTCOMES WERE ASSESSED AT WEEK 12 AND WEEK 24 AFTER RANDOMIZATION. RESULTS: IN TOTAL, 40 WOMEN (MEAN AGE +/- STANDARD DEVIATION, 49.2 +/- 5.9 YEARS) WERE RANDOMIZED TO YOGA (N = 19) OR TO USUAL CARE (N = 21). WOMEN IN THE YOGA GROUP REPORTED SIGNIFICANTLY LOWER TOTAL MENOPAUSAL SYMPTOMS COMPARED WITH THE USUAL CARE GROUP AT WEEK 12 (MEAN DIFFERENCE, -5.6; 95% CONFIDENCE INTERVAL, -9.2 TO -1.9; P = .004) AND AT WEEK 24 (MEAN DIFFERENCE, -4.5; 95% CONFIDENCE INTERVAL, -8.3 TO -0.7; P = .023). AT WEEK 12, THE YOGA GROUP REPORTED LESS SOMATOVEGETATIVE, PSYCHOLOGICAL, AND UROGENITAL MENOPAUSAL SYMPTOMS; LESS FATIGUE; AND IMPROVED QUALITY OF LIFE (ALL P < .05). AT WEEK 24, ALL EFFECTS PERSISTED EXCEPT FOR PSYCHOLOGICAL MENOPAUSAL SYMPTOMS. SHORT-TERM EFFECTS ON MENOPAUSAL SYMPTOMS REMAINED SIGNIFICANT WHEN ONLY WOMEN WHO WERE RECEIVING ANTIESTROGEN MEDICATION (N = 36) WERE ANALYZED. SIX MINOR ADVERSE EVENTS OCCURRED IN EACH GROUP. CONCLUSIONS: YOGA COMBINED WITH MEDITATION CAN BE CONSIDERED A SAFE AND EFFECTIVE COMPLEMENTARY INTERVENTION FOR MENOPAUSAL SYMPTOMS IN BREAST CANCER SURVIVORS. THE EFFECTS SEEM TO PERSIST FOR AT LEAST 3 MONTHS. 2015 9 1650 41 MULTICENTER, RANDOMIZED CONTROLLED TRIAL OF YOGA FOR SLEEP QUALITY AMONG CANCER SURVIVORS. PURPOSE: THIRTY PERCENT TO 90% OF CANCER SURVIVORS REPORT IMPAIRED SLEEP QUALITY POST-TREATMENT, WHICH CAN BE SEVERE ENOUGH TO INCREASE MORBIDITY AND MORTALITY. LIFESTYLE INTERVENTIONS, SUCH AS EXERCISE, ARE RECOMMENDED IN CONJUNCTION WITH DRUGS AND COGNITIVE BEHAVIORAL THERAPY FOR THE TREATMENT OF IMPAIRED SLEEP. PRELIMINARY EVIDENCE INDICATES THAT YOGA-A MIND-BODY PRACTICE AND FORM OF EXERCISE-MAY IMPROVE SLEEP AMONG CANCER SURVIVORS. THE PRIMARY AIM OF THIS RANDOMIZED, CONTROLLED CLINICAL TRIAL WAS TO DETERMINE THE EFFICACY OF A STANDARDIZED YOGA INTERVENTION COMPARED WITH STANDARD CARE FOR IMPROVING GLOBAL SLEEP QUALITY (PRIMARY OUTCOME) AMONG POST-TREATMENT CANCER SURVIVORS. PATIENTS AND METHODS: IN ALL, 410 SURVIVORS SUFFERING FROM MODERATE OR GREATER SLEEP DISRUPTION BETWEEN 2 AND 24 MONTHS AFTER SURGERY, CHEMOTHERAPY, AND/OR RADIATION THERAPY WERE RANDOMLY ASSIGNED TO STANDARD CARE OR STANDARD CARE PLUS THE 4-WEEK YOGA INTERVENTION. THE YOGA INTERVENTION USED THE YOGA FOR CANCER SURVIVORS (YOCAS) PROGRAM CONSISTING OF PRANAYAMA (BREATHING EXERCISES), 16 GENTLE HATHA AND RESTORATIVE YOGA ASANAS (POSTURES), AND MEDITATION. PARTICIPANTS ATTENDED TWO 75-MINUTE SESSIONS PER WEEK. SLEEP QUALITY WAS ASSESSED BY USING THE PITTSBURGH SLEEP QUALITY INDEX AND ACTIGRAPHY PRE- AND POSTINTERVENTION. RESULTS: IN ALL, 410 SURVIVORS WERE ACCRUED (96% FEMALE; MEAN AGE, 54 YEARS; 75% HAD BREAST CANCER). YOGA PARTICIPANTS DEMONSTRATED GREATER IMPROVEMENTS IN GLOBAL SLEEP QUALITY AND, SECONDARILY, SUBJECTIVE SLEEP QUALITY, DAYTIME DYSFUNCTION, WAKE AFTER SLEEP ONSET, SLEEP EFFICIENCY, AND MEDICATION USE AT POSTINTERVENTION (ALL P 3-POINT REDUCTION IN PSQI) AT 12 WEEKS VARIED BY CHANGES IN PAIN AND PHYSICAL FUNCTION AT 6 WEEKS. KEY RESULTS: AMONG PARTICIPANTS (MEAN AGE = 46.0, 64% FEMALE, 82% NON-WHITE), NEARLY ALL (92%) REPORTED POOR SLEEP QUALITY (PSQI > 5) AT BASELINE. AT 12 WEEKS, MODEST IMPROVEMENTS IN SLEEP QUALITY WERE OBSERVED AMONG THE YOGA (PSQI MEAN DIFFERENCE [MD] = - 1.19, 95% CONFIDENCE INTERVAL [CI] - 1.82, - 0.55) AND PT (PSQI MD = - 0.91, 95% CI - 1.61, - 0.20) GROUPS. PARTICIPANTS WHO REPORTED A >/= 30% IMPROVEMENT IN PAIN OR PHYSICAL FUNCTION AT 6 WEEKS, COMPARED WITH THOSE WHO IMPROVED < 10%, WERE MORE LIKELY TO BE A SLEEP QUALITY RESPONDER AT 12 WEEKS (ODDS RATIO [OR] = 3.51, 95% CI 1.73, 7.11 AND OR = 2.16, 95% CI 1.18, 3.95, RESPECTIVELY). RESULTS WERE SIMILAR AT 52 WEEKS. CONCLUSION: IN A SAMPLE OF ADULTS WITH CLBP, VIRTUALLY ALL WITH POOR SLEEP QUALITY PRIOR TO INTERVENTION, MODEST BUT STATISTICALLY SIGNIFICANT IMPROVEMENTS IN SLEEP QUALITY WERE OBSERVED WITH BOTH YOGA AND PT. IRRESPECTIVE OF TREATMENT, CLINICALLY IMPORTANT SLEEP IMPROVEMENTS AT THE END OF THE INTERVENTION WERE ASSOCIATED WITH MID-INTERVENTION PAIN AND PHYSICAL FUNCTION IMPROVEMENTS. TRIAL REGISTRATION: CLINICALTRIALS.GOV IDENTIFIER: NCT01343927. 2020 16 2552 43 YOGA FOR CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY AND FALL RISK: A RANDOMIZED CONTROLLED TRIAL. BACKGROUND: CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) IS A COMMON, DEBILITATING SIDE EFFECT THAT WORSENS QUALITY OF LIFE AND INCREASES THE RISK OF FALLS IN CANCER SURVIVORS. EVIDENCE OF YOGA'S SAFETY AND EFFICACY IN TREATING CIPN IS LACKING. METHODS: IN A RANDOMIZED CONTROLLED STUDY, WE ASSIGNED BREAST AND GYNECOLOGICAL CANCER SURVIVORS WITH PERSISTENT MODERATE-TO-SEVERE CIPN PAIN, NUMBNESS, OR TINGLING WITH A SCORE OF 4 OR GREATER (0-10 NUMERIC RATING SCALE [NRS]) FOR AT LEAST 3 MONTHS AFTER CHEMOTHERAPY TO 8 WEEKS OF USUAL CARE OR YOGA FOCUSED ON BREATHWORK AND MUSCULOSKELETAL CONDITIONING. PRIMARY ENDPOINT WAS TREATMENT ARM DIFFERENCES FOR NRS, AND SECONDARY ENDPOINTS WERE FUNCTIONAL ASSESSMENT OF CANCER THERAPY/GYNECOLOGIC ONCOLOGY GROUP-NEUROTOXICITY SUBSCALE (FACT/GOG-NTX), AND FUNCTIONAL REACH TEST AFTER WEEK 8. WE TESTED TREATMENT ARM DIFFERENCES FOR EACH OUTCOME MEASURE USING LINEAR MIXED MODELS WITH TREATMENT-BY-TIME INTERACTIONS. ALL STATISTICAL TESTS WERE TWO-SIDED. RESULTS: WE RANDOMLY ASSIGNED 41 PARTICIPANTS INTO YOGA (N = 21) OR USUAL CARE (N = 20). AT WEEK 8, MEAN NRS PAIN DECREASED BY 1.95 POINTS (95% CONFIDENCE INTERVAL [CI] = -3.20 TO -0.70) IN YOGA VS 0.65 (95% CI = -1.81 TO 0.51) IN USUAL CARE (P = .14). FACT/GOG-NTX IMPROVED BY 4.25 (95% CI = 2.29 TO 6.20) IN YOGA VS 1.36 (95% CI = -0.47 TO 3.19) IN USUAL CARE (P = .035). FUNCTIONAL REACH, AN OBJECTIVE FUNCTIONAL MEASURE PREDICTING THE RISK OF FALLS, IMPROVED BY 7.14 CM (95% CI = 3.68 TO 10.59) IN YOGA AND DECREASED BY 1.65 CM (95% CI = -5.00 TO 1.72) IN USUAL CARE (P = .001). FOUR GRADE 1 ADVERSE EVENTS WERE OBSERVED IN THE YOGA ARM. CONCLUSION: AMONG BREAST AND GYNECOLOGICAL CANCER SURVIVORS WITH MODERATE-TO-SEVERE CIPN, YOGA WAS SAFE AND SHOWED PROMISING EFFICACY IN IMPROVING CIPN SYMPTOMS. 2020 17 2654 46 YOGA IMPROVES QUALITY OF LIFE AND BENEFIT FINDING IN WOMEN UNDERGOING RADIOTHERAPY FOR BREAST CANCER. THIS STUDY EXAMINED THE EFFECTS OF YOGA ON QUALITY OF LIFE (QOL) AND PSYCHOSOCIAL OUTCOMES IN WOMEN WITH BREAST CANCER UNDERGOING RADIOTHERAPY. SIXTY-ONE WOMEN WERE RANDOMLY ASSIGNED TO EITHER A YOGA OR A WAIT-LIST GROUP. YOGA CLASSES WERE TAUGHT BIWEEKLY DURING THE 6 WEEKS OF RADIOTHERAPY. PARTICIPANTS COMPLETED MEASURES OF QOL, FATIGUE, BENEFIT FINDING (FINDING MEANING IN THE CANCER EXPERIENCE), INTRUSIVE THOUGHTS, SLEEP DISTURBANCES, DEPRESSIVE SYMPTOMS, AND ANXIETY BEFORE RADIOTHERAPY AND THEN AGAIN 1 WEEK, 1 MONTH, AND 3 MONTHS AFTER THE END OF RADIOTHERAPY. GENERAL LINEAR MODEL ANALYSES REVEALED THAT COMPARED TO THE CONTROL GROUP, THE YOGA GROUP REPORTED SIGNIFICANTLY BETTER GENERAL HEALTH PERCEPTION (P = .005) AND PHYSICAL FUNCTIONING SCORES (P = .04) 1 WEEK POSTRADIOTHERAPY; HIGHER LEVELS OF INTRUSIVE THOUGHTS 1 MONTH POSTRADIOTHERAPY (P = .01); AND GREATER BENEFIT FINDING 3 MONTHS POSTRADIOTHERAPY (P = .01). THERE WERE NO OTHER GROUP DIFFERENCES IN OTHER QOL SUBSCALES FOR FATIGUE, DEPRESSION, OR SLEEP SCORES. EXPLORATORY ANALYSES INDICATED THAT INTRUSIVE THOUGHTS 1 MONTH AFTER RADIOTHERAPY WERE SIGNIFICANTLY POSITIVELY CORRELATED WITH BENEFIT FINDING 3 MONTHS AFTER RADIOTHERAPY (R = .36, P = .011). OUR RESULTS INDICATED THAT THE YOGA PROGRAM WAS ASSOCIATED WITH STATISTICALLY AND CLINICALLY SIGNIFICANT IMPROVEMENTS IN ASPECTS OF QOL. 2010 18 2529 37 YOGA EFFECTIVELY REDUCES FATIGUE AND SYMPTOMS OF DEPRESSION IN PATIENTS WITH DIFFERENT TYPES OF CANCER. PURPOSE: EXAMINE THE EFFECTS OF AN 8-WEEK YOGA THERAPY ON FATIGUE IN PATIENTS WITH DIFFERENT TYPES OF CANCER. METHODS: A TOTAL OF 173 CANCER PATIENTS SUFFERING FROM MILD TO SEVERE FATIGUE WERE RANDOMLY ALLOCATED TO YOGA INTERVENTION (N = 84) (IG) VERSUS WAITLIST CONTROL GROUP (CG) (N = 88). YOGA THERAPY CONSISTED OF EIGHT WEEKLY SESSIONS WITH 60 MIN EACH. THE PRIMARY OUTCOME WAS SELF-REPORTED FATIGUE SYMPTOMS. SECONDARY OUTCOMES WERE SYMPTOMS OF DEPRESSION AND QUALITY OF LIFE (QOL). DATA WERE ASSESSED USING QUESTIONNAIRES BEFORE (T0) AND AFTER YOGA THERAPY FOR IG VERSUS WAITING PERIOD FOR CG (T1). RESULTS: A STRONGER REDUCTION OF GENERAL FATIGUE (P = .033), PHYSICAL FATIGUE (P = .048), AND DEPRESSION (P < .001) AS WELL AS A STRONGER INCREASE IN QOL (P = .002) WAS FOUND FOR PATIENTS WHO ATTENDED 7 OR 8 SESSIONS COMPARED WITH CONTROLS. WITHIN THE YOGA GROUP, BOTH HIGHER ATTENDANCE RATE AND LOWER T0-FATIGUE WERE SIGNIFICANT PREDICTORS OF LOWER T1-FATIGUE (P